Allogene TherapeuticsALLO
ALLO
About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Employees: 361
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
192% more call options, than puts
Call options by funds: $444K | Put options by funds: $152K
56% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 41
50% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]
0.75% more ownership
Funds ownership: 89.98% [Q4 2024] → 90.73% (+0.75%) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 29
2% less funds holding
Funds holding: 173 [Q4 2024] → 170 (-3) [Q1 2025]
25% less capital invested
Capital invested by funds: $402M [Q4 2024] → $302M (-$100M) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
199%
upside
Avg. target
$8.14
508%
upside
High target
$10
646%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Samantha Semenkow | 199%upside $4 | Buy Maintained | 15 May 2025 |
Truist Securities Asthika Goonewardene | 646%upside $10 | Buy Maintained | 14 May 2025 |
Piper Sandler Biren Amin | 422%upside $7 | Overweight Maintained | 14 May 2025 |
RBC Capital Luca Issi | 646%upside $10 | Outperform Reiterated | 14 May 2025 |
Oppenheimer Matthew Biegler | 572%upside $9 | Outperform Maintained | 14 May 2025 |
Financial journalist opinion
Based on 7 articles about ALLO published over the past 30 days
Positive
Zacks Investment Research
3 days ago
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
2 weeks ago
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells.
Positive
Seeking Alpha
2 weeks ago
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, especially for ALLO-316 in solid tumors, could be a major catalyst and validate Allogene's platform for broader indications. Despite immense upside potential, significant risks remain: safety, execution, regulatory uncertainty, and likely dilution due to future fundraising needs.
Positive
Seeking Alpha
2 weeks ago
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong cash runway and prudent expense management. Key strengths include a differentiated allogeneic CAR-T platform and strategic partnerships, though clinical and regulatory risks remain significant.
Neutral
GlobeNewsWire
3 weeks ago
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June.
Neutral
GlobeNewsWire
3 weeks ago
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.
Negative
Zacks Investment Research
1 month ago
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Neutral
Seeking Alpha
1 month ago
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Biren Amin - Piper Sandler Brian Chang - JPMorgan Matthew Biegler - Oppenheimer Samantha Semenkow - Citi John Newman - Canaccord Genuity William Pickering - Bernstein Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter and 2025 Conference Call.
Charts implemented using Lightweight Charts™